Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Introduction to Superior Vena Cava (SVC) Syndrome
Dr West
2008
Author
Howard (Jack) West, MD

Superior vena cava (SVC) syndrome is an infrequent but not rare complication of lung cancer, occurring in 2-4% of cases, most typically an early symptom that leads to the diagnosis. The SVC is the main vein that drains blood back into the heart from the upper body, and it runs in the middle of the chest on the right side, where it is vulnerable to being compressed by a nearby lung cancer or enlarged lymph nodes, such as from lung cancer or lymphoma. Less commonly, SVC syndrome can be caused by a clot within the blood vessel, and it's also possible to have a combination of external compression and blood clot (clots are more likely to develop where blood flow is compromised). This leads to blockage of the blood flow from the upper body and engorged blood vessels and often swelling of the face, neck, and sometimes upper extremities, as shown in this figure (from this summary article): SVC syndrome The leading symptoms of SVC syndrome are facial edema, distended veins in the neck and sometimes chest, arm edema, shortness of breath, cough, facial plethora/fullness, and less commonly wheezing, lightheadedness, headaches, and even confusion.

Although several decades ago infectious issues such as syphylis and TB were common causes of SVC syndrome, it's much more common now to have cancer as a cause today. Specifically, this is usually lung cancer, but lymphoma can also lead to this, and more rarely causes like germ cell tumors in the chest. A few decades ago, cancer was the source of up to 90% of SVC syndromes, but now that indwelling catheters and pacemakers are more common and can lead to clotting within the blood vessels, cancer is the cause in only about 2/3 of cases. The best way to assess this is with a chest CT with intravenous contrast, although ultrasound studies of the upper extremities (OK, arms) can help identify the extent of the backup; MRI scans are also sometimes used, but generally in people who can't receive IV contrast. The diagnosis is made by obtaining tissue, which is sometimes done by draining pleural fluid, since up to 2/3 of patients with SVC syndrome also have a pleural effusion. Whie a thoracentesis (removing fluid around the lung with a needle from the back) is relatively can provide some relief of shortness of breath, it only yields a diagnosis about half of the time. Bronchoscopy works about 50-70% of the time, CT-guided biopsy with a needle from outside of the chest about 75% of the time, and mediastinoscopy somewhere in the range of 90% of the time. Another potential biopsy source would be to excise an enlarged lymph node, such as above the clavicle, which has the advantage of providing a significant amount of tissue to examine. Particularly for lymphoma but also for lung cancer and other malignant causes, haivng more tissue to review is always helpful. Next, we'll turn to management of SVC syndrome.

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on